Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Group 1 - Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, fulfilling obligations under the Option Agreement, resulting in total returns of $118 million on a $99.5 million investment [1][2] - Oramed retains a $27 million note and a $12 million convertible note with Scilex, convertible into equity at $36 per share, with repayment scheduled through October 2026 if not converted [2] - The Board of Directors approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, funded by surplus capital [3] Group 2 - Oramed is a clinical-stage pharmaceutical company focused on oral delivery solutions for injectable drugs, utilizing its Protein Oral Delivery (POD™) technology [4]